VASCULAR THROBOSIS PREVENTION IN ARTERY SURGERY P. Niedziela J. Michalak W. Kobusiewicz,P. Niedziela J. Michalak W. Kobusiewicz, Department of Vascular.

Slides:



Advertisements
Similar presentations
Nursing Care & Interventions for Clients with Vascular Problems
Advertisements

Venous Thrombo-embolism In Pregnancy
Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.
Preventing VTE in Surgical Patients. Today’s Topics The common sense science of VTE prevention Brief history of VTE prevention techniques High yield methods.
Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.
DVT PROPHYLAXIS SUNDIP PATEL 7 / 15 / BACKGROUND Deep Vein Thrombosis is a common, yet preventable peri-operative complication Highest risk in critical.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Prophylaxis of Venous Thromboembolism
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Venous Thromboembolism
Deep Vein Thrombosis (DVT)
RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.
Medications that impact bleeding By Nino Lalaiants Inesa Legrian NYCCT 2012.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
DVT/VTE Nursing Protocol (Deep Vein Thrombosis) (Venous Thromboembolism) Presented by Maribeth Desiongco MA, RN-BC 2008.
Approximately 600,000 new cases are diagnosed in the U.S. each year Thrombus formation in deep veins of legs or thighs Tibial veins, soleal/gastrocnemius.
DVT & VARICOSE VEINS.
1. 2 Definition Definition Causes Causes Risk Factors Risk Factors Symptoms Symptoms Importance Importance Treatments Treatments Content Introduction.
Thrombo means “clot” and phlebitis is the inflammation of a vein. This occurs when a blood clot causes inflammation in one or more of your veins, specially.
Total Joint Replacement
Study Guide Guide for Patients Undergoing Anticoagulant Therapy.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Postoperative venous thromboembolic disease prevention in the neurosurgery population Ahmad Khaldi, M.D. 1 Michael Wall, PharmD 2 T.C. Origitano, M.D.,
Thromboprophylaxis in Pregnancy and the Puerperium
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.
1 VTE Protocol Presented by: Selina Baskins, RN Quality Coordinator.
IMPLEMENTING GUIDELINES AND REDUCING PATIENT RISK OF VENOUS THROMBOEMBOLISM IN A LARGE UK TEACHING HOSPITAL Sharron Millen, Head of Clinical Pharmacy and.
Anticoagulants By: Darrel Dejvongsa. About Anticoagulants Anticoagulants also called Blood Thinners help prevent existing blood clots form becoming larger.
Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Peripheral Vascular Disease Megan McClintock. Peripheral Artery Disease Definition Etiology/Pathophysiology Signs & symptoms Complications Diagnostic.
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
VTE Prevention In Action Interactive Case Scenarios.
Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,
Venous Thromboembolism Prophylaxis for Medical Inpatients Heather Hofmann, rev. 4/18/14 DSR2 Mini Lecture.
Pulmonary Embolism Pulmonary embolism is blockage in one or more arteries in your lungs. Maggie Trainor.
DVT & PE: How early can I mobilize a patient ??
Risk Assessment for VTE. Which of the following best describes you?
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Low risk: young, with minor illnesses, who are to undergo operations lasting 30 min or less. Moderate risk: over 40 or with a debilitating illness who.
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.
Pulmonary Embolism Dr. Gerrard Uy.
Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.
Anticoagulant Therapy
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
1 MMM October 2008 AVAIL ME Project Audit of Venous Thromboembolism Management in Middle East Hospitals Elham Mir,MD MPH Medical Affairs Clinical Operation.
Dr. Lesbia Adalgisa Rodriguez PGY3-Cook County Loyola Family Medicine Residency Program Venous Thromboembolism Prophylaxis in the Inpatient Setting.
Outpatient DVT assessment & treatment Daniel Gilada.
Coagulation and anti-coagulants March Normal physiology Patophysiology Diagnostic tests Anticoagulants Anticoagulants and anesthesia.
Copyright © 2003 American Medical Association. All rights reserved.
Fig. 2. Comparative efficacy of thromboprophylaxis interventions in the prevention of deep vein thrombosis (DVT). (A) Estimated odds ratios (ORs) and 95%
pharmacotherapeutics III Case presentation on deep vein thrombosis
From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.
Thrombosis, Cancer, and NOACs
Owen N. Johnson, MD, David L
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis  Paloma López-Beret, MD, Antonio Orgaz, MD,
New oral anticoagulants—what the cardiothoracic surgeon needs to know
Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer 
Don't look now! Risk stratify first
Succinct Review of the New VTE Prevention and Management Guidelines
GHS Outpatient Enoxaparin Program
Cancer-Associated Thrombosis
by Alex C. Spyropoulos, and James D. Douketis
How I treat cancer-associated venous thromboembolism
Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.
Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Khashayar Salartash, MD, Mark D
Presentation transcript:

VASCULAR THROBOSIS PREVENTION IN ARTERY SURGERY P. Niedziela J. Michalak W. Kobusiewicz,P. Niedziela J. Michalak W. Kobusiewicz, Department of Vascular Surgery Medical Academy, Lublin, Poland PRAGUE 2002

thrombosis in case obesity age above 40 malignant cancers hormonal drug varicose veins

< 1 hours 57 % 1 – 3 hours 35 % > 3 hours 8 %

methods physicalpharmacological

Standard heparin Standard heparin LMWH LMWH Dextran Dextran Oral anticoagulants Oral anticoagulants Acetylsalicylic acid Acetylsalicylic acid

low risk low risk medium risk medium risk high risk high risk

age up 40 have undergone operative treatments without clinical risk factors

more than 40 years old major arterial treatments without clinical risk factors

above 40 years old vast reconstructive operations with additional risk factors

Prophylaxis of deep vein thrombosis standard heparin standard heparin low molecular weight heparin low molecular weight heparin

Fraxiparin0,01ml/kg Clexane 1 mg/ kg Clivarin jm/kg

fewer complications fewer complications lower cost of treatment lower cost of treatment convenient way of administration convenient way of administration